INTRODUCTION {#s1}
============

Chordoma is a rare, locally aggressive, and invasive cancer arising from the notochord, which is a cartilage-like mesodermal rod. In vertebrates, the notochord is a precursor to the intervertebral disc. Chordoma is considered a malignant tumor of bone and accounts for 1%--4% of such tumors. The incidence is \<1/1,000,000 per year and approximately 22 cases are diagnosed per year in the United States.

Chordoma may arise anywhere along the cranio-spinal axis. In adults, 50% of the cases involve the sacro-coccygeal region, 35% occur at the base of the skull, and 15% are found elsewhere in the vertebral column ([@MCS003418LIAC12]). Gross total resection is typically limited by the cancer\'s proximity to critical neurovascular structures. Thus, adjuvant radiotherapy is used routinely. Patients have a median survival of 7.7 yr ([@MCS003418LIAC53]); the survival rate is ∼70%--72% at 5 yr and falls to 40%--48% at 10 yr ([@MCS003418LIAC53]; [@MCS003418LIAC9]).

The brachyury (*T*, T-box transcription factor T) protein is essential for notochord differentiation. Expression of the *T* gene is used to differentiate chordoma from other chondroid tumors ([@MCS003418LIAC61]; [@MCS003418LIAC42]). A germline single-nucleotide polymorphism (SNP) within the DNA-binding region of brachyury has been strongly associated with the risk of developing sporadic chordoma, whereas duplication of the *T* gene has been reported in the rare familial form of chordoma ([@MCS003418LIAC64]).

Previous analyses have led to the identification of pathological changes in chordomas. Such changes include transcriptomic changes ([@MCS003418LIAC7]), as well as point mutations and copy-number losses in genes such as *ALK*, *CDKN2A*, *NRAS*, *PTEN*, *NBPF1*, *SETD2*, and *SMARCB1* ([@MCS003418LIAC23]; [@MCS003418LIAC31]; [@MCS003418LIAC10]; [@MCS003418LIAC20]; [@MCS003418LIAC62]; [@MCS003418LIAC45]; [@MCS003418LIAC14]), whose loss characterizes poorly differentiated chordomas ([@MCS003418LIAC38]). Of note, loss of INI1/SMARCB1 may also represent a discrete entity with a more aggressive phenotype more similar to rhabdoid tumors ([@MCS003418LIAC25]). As a rare and typically fatal condition with a complex etiology, and given the variety of molecular mechanisms that may be responsible for the development of this tumor, chordoma may be a candidate for individualized approaches to molecularly targeted treatment. Thus, in this study, we performed next-generation DNA and RNA sequencing of paired chordoma and germline samples to build on our understanding of the genomic and transcriptomic landscape of chordoma and to identify potentially actionable alterations that may be worth exploring further in clinical trials.

RESULTS {#s2}
=======

Across the four chordoma patients ([Table 1](#MCS003418LIATB1){ref-type="table"}), a mean target coverage of 165× was achieved for the tumors and 112× for the germline exomes. From the long-insert whole genomes (LIWGs), a mean clonal coverage of 43× was achieved for the tumors and 44× for the germline samples. A mean of 195 million paired reads was generated across the tumor RNAs using RNA-seq (RNA sequencing). The total number of somatic alterations identified in each patient\'s tumor (loss of function, missense, intronic, in-frame indel, splice site loss, splicing altered, untranslated region \[UTR\]) were 24, 32, 2, and 22, respectively for Patients 1--4. The brachyury (*T*) SNP rs2305089 was observed in all the tumors ([@MCS003418LIAC42]) along with elevated expression of *T* in Patients 1, 2, and 4 with FPKMs of 155.5, 398.2, and 442.9, respectively. [Table 2](#MCS003418LIATB2){ref-type="table"} lists the DNA or RNA alterations that were identified through sequencing and that are potentially targetable with an FDA-approved agent. For those genes associated with a drug--gene rule, any additional alterations that were detected in those genes across the cohort are also listed. Additional somatic alterations implicated in chordoma or other cancers (*ALK*, *CDKN2A*, *NRAS*, *PTEN*, *SMARCB1*, *NBPF1*, *TP3*) and potential pathogenic germline variants were also evaluated. Herein, we present clinical information, pathology results, and representative imaging data for each patient, as well as the results from sequencing and drug--gene analyses.

###### 

Summary of patients

  Patient   Gender   Age at diagnosis   Ethnicity   Location       Tumor purity (%)^a^
  --------- -------- ------------------ ----------- -------------- ---------------------
  1         M        70                 Caucasian   Sacral         36
  2         M        57                 Caucasian   Sacral         74
  3         M        29                 Caucasian   Sacral         33
  4         M        54                 Caucasian   Petro-clival   44

Phenotypic information for each patient is shown.

^a^Tumor purities were estimated in silico using Sequenza ([@MCS003418LIAC19]).

###### 

Selected aberrations and associated drug matches

  Patient     Gene                                                     Gene name                               Variant type^a^         Chromosomal location   Alteration                        Description         HGVS cDNA       Tumor DNA allele frequency^b^   Constitutional DNA allele frequency^b^   HGVS protein   ClinVar variation ID                     ClinVar clinical significance                    Predicted effect (MutationTaster/PolyPhen-2/FATHMM)^c^   Genotype (HM/HT)                 Drug matches
  ----------- -------------------------------------------------------- --------------------------------------- ----------------------- ---------------------- --------------------------------- ------------------- --------------- ------------------------------- ---------------------------------------- -------------- ---------------------------------------- ------------------------------------------------ -------------------------------------------------------- -------------------------------- --------------------------
  1           *FGFR1*                                                  Fibroblast growth factor receptor 1     Overexpression          Chr 8: 38,268,655      log~2~ fold = 3.3 (Q^d^ = 0.03)   N/A                 N/A             N/A                             N/A                                      N/A            N/A                                      N/A                                              N/A                                                      N/A                              Ponatinib, pazopanib
  *PIP4K2A*   Phosphatidylinositol-5-phosphate 4-kinase type 2α        Substitution                            Chr 10: 22,825,649      A\>C                   UTR                               c.\*481T\>G         0.16 (5/31)     0.0 (0/19)                      N/A                                      N/A            Not reported                             N/A                                              HT                                                       Palbociclib                      
  *T*         Brachyury                                                Substitution                            Chr 6: 166,579,270      G\>A                   G177D; rs2305089                  c.530G\>A           0.48 (55/114)   0.54 (43/79)                    p.Gly177Asp                              N/A            Not reported                             P/B/T                                            HT                                                       N/A                              
  2           *CDK4*                                                   Cyclin-dependent kinase 4               Copy gain               Chr 12: 55,640,800     log~2~ fold = 1.5                 N/A                 N/A             N/A                             N/A                                      N/A            441984                                   Pathogenic                                       N/A                                                      N/A                              Palbociclib, abemaciclib
  *ERBB3*     erb-b2 receptor tyrosine kinase 3                        Copy gain                               Chr 12: 55,640,800      log~2~ fold = 1.5      N/A                               N/A                 N/A             N/A                             N/A                                      441984         Pathogenic                               N/A                                              N/A                                                      Afatinib, gefitinib, lapatinib   
  *GLI1*      GLI family zinc finger 1                                 Copy gain                               Chr 12: 55,640,800      log~2~ fold = 1.5      N/A                               N/A                 N/A             N/A                             N/A                                      441984         Pathogenic                               N/A                                              N/A                                                      Arsenic trioxide                 
  *GLI1*      GLI family zinc finger 1                                 Substitution                            Chr 12: 57,864,709      C\>T                   T729I                             c.2186C\>T          0.09 (31/359)   0.0 (0/101)                     p.Thr729Ile                              N/A            Not reported                             N/B/T                                            HT^e^                                                    N/A                              
  *GLS2*      Glutaminase 2                                            Copy gain                               Chr 12: 55,640,800      log~2~ fold = 1.5      N/A                               N/A                 N/A             N/A                             N/A                                      441984         Pathogenic                               N/A                                              N/A                                                      Temozolomide                     
  *PIP4K2A*   Phosphatidylinositol-5-phosphate 4-kinase type 2 alpha   Substitution                            Chr 10: 22,898,627      A\>T                   V55D                              c.164T\>A           0.78 (25/32)    0.0 (0/54)                      p.Val55Asp                               N/A            Not reported                             D/D/T                                            HM                                                       Palbociclib                      
  *T*         Brachyury                                                Substitution                            Chr 6: 166,579,270      G\>A                   G177D; rs2305089                  c.530G\>A           1.0 (109/109)   1.0 (75/76)                     p.Gly177Asp                              N/A            Not reported                             P/B/T                                            HM                                                       N/A                              
  *TP53*      Tumor protein p53                                        Copy loss                               Chr 17: 5,003,600       log~2~ fold = −0.7     N/A                               N/A                 N/A             N/A                             N/A                                      149158         Pathogenic                               N/A                                              N/A                                                      N/A                              
  *IGF1R*     Insulin-like growth factor 1 receptor                    Substitution                            Chr 15: 99,502,153      T\>G                   UTR                               c.\*1482T\>G        0.28 (34/122)   0.00 (0/83)                     N/A                                      N/A            Not reported                             N/A                                              HT                                                       Ganitumab^f^                     
  3           *ATM*                                                    ATM serine/threonine kinase             Germline substitution   Chr 11: 108,119,823    T\>C                              V410A; rs56128736   c.1229T\>C      0.49 (19/39)                    0.41 (23/56)                             p.Val410Ala    127332                                   Conflicting (benign; likely benign; uncertain)   D/B/T                                                    HT                               Olaparib, niraparib
  *CHEK2*     Checkpoint kinase 2                                      Germline substitution                   Chr 22: 29,091,178      G\>T                   D481Y; rs200050883                c.1441G\>T          0.56 (79/141)   0.62 (66/107)                   p.Asp481Tyr                              128056         Conflicting (likely benign; uncertain)   D/D/T                                            HT                                                       Olaparib, niraparib              
  *T*         Brachyury                                                Substitution                            Chr 6: 166,579,270      G\>A                   G177D; rs2305089                  c.530G\>A           1.0 (112/112)   1.0 (87/87)                     p.Gly177Asp                              N/A            Not reported                             P/B/T                                            HM                                                       N/A                              
  4           *IGF1R*                                                  Insulin-like growth factor 1 receptor   Substitution            Chr 15: 99,460,066     T\>G                              V721G               c.2162T\>G      0.04 (9/206)                    0.0 (0/142)                              p.Val721Gly    N/A                                      Not reported                                     D/P/T                                                    N/A^e^                           Ganitumab^f^
  *PBRM1*     Polybromo 1                                              Substitution                            Chr 3: 52,668,696       A\>G                   F408S                             c.1223T\>C          0.24 (19/78)    0.0 (0/91)                      p.Phe408Ser                              N/A            Not reported                             D/D/T                                            HT                                                       N/A                              
  *T*         Brachyury                                                Substitution                            Chr 6: 166,579,270      G\>A                   G177D; rs2305089                  c.530G\>A           0.59 (60/102)   0.37 (30/81)                    p.Gly177Asp                              N/A            Not reported                             P/B/T                                            HT                                                       N/A                              

^a^Variants listed are somatic unless indicated as germline.

^b^Allele frequencies are shown as the ratio of the \# alternate reads/\# total reads.

^c^Predicted effect: predicted functional impact based on MutationTaster, PolyPhen-2, and FATHMM. D, Damaging; P, possibly damaging; B, benign; N, neutral; T, tolerated.

^d^*Q*-value, corrected *P*-value using the Benjamini--Hochberg correction for multiple testing.

^e^Subclonal event identified using exome sequencing.

^f^Investigational agent.

Sacral Chordomas {#s2a}
----------------

### Patient 1 {#s2a1}

A 70-yr-old male patient presented with a 14 × 11 × 20-cm predominantly presacral mass and bony destruction of the distal sacrum and coccyx, as well as multiple amorphous calcifications. Surgery consisted of an S1--S3 laminectomy with *en bloc* resection of S3 and removal of the distal sacrum and coccyx ([Fig. 1](#MCS003418LIAF1){ref-type="fig"}, upper row). Pathology reported the tumor to be chondromyxoid, with mild atypia and no mitoses or necrosis, as well as positive immunohistochemistry (IHC) for S100 and keratin AE1/AE3. Eleven months after diagnosis, a magnetic resonance imaging (MRI) showed recurrent local disease ([Fig. 1](#MCS003418LIAF1){ref-type="fig"}, lower row), with pelvic and inguinal lymphadenopathy and pulmonary metastases. He began palliative treatment with intensity-modulated radiotherapy (IMRT) at that time with 15 × 2.5 = 37.5 Gy to the entire pelvis and an additional 5 × 2.5 = 12.5 Gy to the tumor, along with imatinib (400 mg daily). He developed intercurrent pneumonia and was transferred to hospice care.

![Patient 1 MRI images. All images are sagittal in midline. Panels in the *left* column (*A*,*C*) are T2-weighted, fast-spin echo, whereas those in the *right* column (*B*,*D*) are T1-weighted with contrast (T1 + Gd). Panels shown in the *upper* row (*A*,*B*) are postoperative, following initial gross total resection. Resection of the vertebrae caudal to S1 is indicated with the blue arrow. Panels in the *lower* row (*C*,*D*) were taken at time of recurrence. A large, heterogeneous mass extending rostrally almost to S1 and dorsally almost to the skin is present (blue arrows). The dimensions are almost equal to those of the tumor prior to initial resection.](MCS003418Lia_F1){#MCS003418LIAF1}

Tumor DNA sequencing revealed no definitive therapeutic targets. However, a somatic point mutation in the UTR of *PIP4K2A* was identified and may thus impact transcriptional regulation of the gene. PIP4K2A has been reported to be essential for cell proliferation in acute myeloid leukemia, through AKT/mTOR activation and cell cycle regulation ([@MCS003418LIAC29]), and has also been found to be a target of the CDK4/6 inhibitor palbociclib ([@MCS003418LIAC56]). Although *PIP4K2A* expression was not significantly up-regulated compared to a universal human control, expression of the gene was observed, with a FPKM of 17.8. Clinical trials are currently underway evaluating palbociclib as a single agent in advanced chordoma (NCT03110744), and in *CDK4*-amplified solid tumors (NCI Match, NCT02465060).

Overexpression of *FGFR1* compared to a universal RNA control was also observed in Patient 1\'s tumor. The FGF pathway has been implicated in chordoma as a driver of brachyury overexpression ([@MCS003418LIAC39]; [@MCS003418LIAC28]), which was observed in this patient\'s tumor. In preclinical models, chordoma cell lines express both *FGFR2* and *FGFR3* and are sensitive to FGFR inhibition ([@MCS003418LIAC28]). FDA-approved agents that target FGFRs include ponatinib, a pan-FGFR inhibitor, and pazopanib, a multityrosine-kinase inhibitor, which also has activity against VEGFR and PDGFR ([@MCS003418LIAC48]; [@MCS003418LIAC22]). Several other FGFR inhibitors are also in clinical development.

With the availability of RNA-seq data, we further evaluated the expression of factors downstream from *FGFR1* to determine if evidence for pathway activation is present. Genes downstream from FGFR demonstrated expression (FPKM \> 1) with a mean FPKM of 42.7 (see Methods), but none demonstrated differential expression compared to a universal RNA control (corrected *P* \< 0.05). Eight of 22 genes demonstrated higher levels of expression with FPKMs of \>42.7 and ranging from 46.9 to 147.0. Although these data are not confirmatory of FGFR pathway activation, such data provide evidence that it is possible that pathway activation may have been present in this patient\'s tumor.

### Patient 2 {#s2a2}

A 57-yr-old male presented with a 15 × 14 × 6-cm sacral mass. The two-stage surgery included a sacrectomy with S1 and S2 interspace embolization followed by closure of a myocutaneous flap. His postoperative MRI is shown in [Figure 2](#MCS003418LIAF2){ref-type="fig"}. Pathology showed a tumor arranged in cords and lobules within a myxoid background and no mitoses or necrosis. A focus of lymphovascular invasion was identified. Four years after diagnosis, recurrence was noted along the borders of the resection cavity. He enrolled in a Phase 2 clinical trial (NCT02383498) of IMRT (70 Gy) with placebo versus a brachyury vaccine (GI-6301). Three years later, he remained free of further progression and continued to use the vaccine every 3 mo, according to the trial protocol.

![Patient 2 MRI images. Images for Patient 2 after his initial resection. (*A*) T2-weighted, with fat saturation via short-tau inversion recovery (STIR). (*B*) T1 + Gd. As with Patient 1 ([Fig. 1](#MCS003418LIAF1){ref-type="fig"}A,B), resection of the vertebrae caudal to S1 is seen (blue arrow).](MCS003418Lia_F2){#MCS003418LIAF2}

Sequencing revealed somatic DNA alterations clustered within regions of Chromosome 12 that are associated with targets for FDA-approved drugs, such as *CDK4* and *ERBB3*. For instance, *CDK4* amplification commonly occurs in liposarcomas, and the CDK4/6 inhibitor palbociclib showed activity in a Phase 2 trial for advanced liposarcoma ([@MCS003418LIAC16]). In chordoma cell lines lacking p16, likely as a result of *CDKN2A* loss, *CDK4/6* gene expression was observed to suggest the possibility of activation in this pathway ([@MCS003418LIAC60]). Subsequent treatment of these lines with the CDK4/6 inhibitors palbociclib and abemaciclib inhibited cell growth to demonstrate the potential efficacy of this treatment strategy. In addition, overexpression of *ERBB3* correlated with gefitinib sensitivity in a preclinical lung cancer model ([@MCS003418LIAC60]) to suggest that ERBB inhibitors or monoclonal antibodies may have activity in this context. Although the expression levels of *CDK4* and *ERBB3* were not significantly altered compared to a universal RNA reference (*P* \> 0.05), both genes demonstrated expression with FPKMs of 80.5 and 76.3, respectively. Furthermore, although variants associated with *CDKN2A* loss were not observed in the DNA, *CDKN2A* expression was low, with a FPKM of 3.5.

Sequencing also revealed alterations in *GLI1* and *GLS2*, which encode candidate drug targets. For instance, arsenic trioxide binds GLI1 to inhibit transcription and cell growth in a cell culture model of Ewing sarcoma ([@MCS003418LIAC5]). In Patient 2\'s tumor, a missense mutation in *GLI1* was detected at a low DNA allele frequency (0.08), but there were no changes in the RNA expression. Furthermore, *GLS2* overexpression is associated with decreased MGMT expression and increased sensitivity to temozolomide in a cell culture model of glioblastoma ([@MCS003418LIAC57]). In Patient 2\'s tumor, the *GLS2* copy number was increased but there were no changes in gene expression. Unlike *CDK4* and *ERBB3*, *GLI1* and *GLS2* demonstrated low expression, with FPKMs of 1.6 and 2.7, respectively.

Other potentially pathogenic somatic abnormalities were observed, although these do not suggest a specific treatment strategy. An expressed missense mutation in *PIP4K2A* was detected (RNA allele frequency \[RAF\] = 0.28), along with low-level loss of *TP53* (log~2~ = −0.7). This specific *PIP4K2A* mutation has not been previously reported or characterized, and the functional consequence is unclear. However, as discussed above, *PIP4K2A* has been identified as a potential target of palbociclib, raising interest in evaluating the CDK4/6 inhibitor in this setting. A heterozygous *IGF1R* UTR point mutation was also observed. *IGF1R* has been implicated in chordoma, as ∼40% of chordomas demonstrate IGF1R/IR signaling activation and IGF1R is correlated with chordoma tumor volume ([@MCS003418LIAC54]; [@MCS003418LIAC47]). Additionally, UTR variants have been proposed to regulate *IGF1R* expression. In this tumor, elevated expression of *IGF1R* was observed with an FPKM of 45.7, although the gene was not significantly overexpressed compared to a universal RNA reference (*P* \> 0.05). The investigational IGF1R antibody, ganitumab, is currently being evaluated in clinical trials for other tumor types.

### Patient 3 {#s2a3}

An incidental presacral mass was identified in a 29-yr-old male who had experienced chronic tailbone pain since age 18. The 4.5 × 8.5 × 4.5-cm tumor was removed *en bloc* ([Fig. 3](#MCS003418LIAF3){ref-type="fig"}), and the chronic pain resolved. Pathology showed physaliferous cells arranged in cords, sheets, and nests, forming cyst-like masses separated by fibrocollagenous septa, within a myxoid background. Mild to moderate atypia was noted. IHC for S100, keratin AE1/AE3, and EMA confirmed the diagnosis. Focal invasion of the resection margins was noted. Proton beam radiotherapy was completed, 1.8 × 42 = 75.6 Gy, and 8 yr following resection, there were no signs of progression clinically or on MRI.

![Patient 3\'s MRI images. Postoperative images for Patient 3. (*A*) T2-weighted, fat saturated (STIR). (*B*) T1 + Gd. These images are largely normal; signs of resection of the presacral mass are present (blue arrows).](MCS003418Lia_F3){#MCS003418LIAF3}

No somatic DNA or RNA alterations were found to be associated with the targets for FDA-approved drugs. However, evaluation of germline data led to the identification of rare missense mutations in *CHEK2* (D481Y; population allele frequency \[PAF\] = 0.001) and *ATM* (V410A; PAF = 0.004). These genes encode proteins involved in DNA damage response and thus may have predisposed the patient to cancer. The same germline *ATM* mutation has been described in breast and ovarian cancer, as well as in acute lymphoblastic leukemia ([@MCS003418LIAC58]; [@MCS003418LIAC35]; [@MCS003418LIAC8]). The *CHEK2* mutation we identified is located in the protein kinase domain. Although this mutation has not been reported, similar *CHEK2* germline mutations have been reported in Li--Fraumeni syndrome ([@MCS003418LIAC6]) and breast cancer ([@MCS003418LIAC3]; [@MCS003418LIAC18]). Both mutations were found in the tumor, although loss of the other allele was not detected in the tumor for either gene. The overall expression of *CHEK2* was low in the tumor (FPKM = 3.6), whereas *ATM* expression was elevated (FPKM = 52.4). Clinical trials are underway evaluating PARP inhibitors (olaparib, niraparib, talazoparib) in tumors with homologous recombination deficiency, including tumors with ATM or CHEK2 loss (e.g., TAPUR, NCT02693535; NCT02286687; NCT03375307). Inhibition of ATM is also being explored and such treatment has been shown to radiosensitize glioma cells ([@MCS003418LIAC21]). The patient\'s younger age supports the hypothesis that these mutations may be pathogenic ([@MCS003418LIAC9]).

Chordoma of Clivus {#s2b}
------------------

### Patient 4 {#s2b1}

A 54-yr-old male was diagnosed with a petro-clival mass and significant brainstem compression. Three-stage resection ([Fig. 4](#MCS003418LIAF4){ref-type="fig"}, after Stage 1) was followed by adjuvant Cyber Knife radiosurgery to remove residual tumor. Pathology showed sheets of cells (physaliferous or epithelioid) within a chondromyxoid background. As with Patient 3, IHC for S100, keratin AE1/AE3, and EMA was confirmatory. The MIB-1 labeling index was 1%, and no mitoses were seen. The patient remains free of progression 18 mo after initial diagnosis.

![Patient 4\'s MRI images. Images recorded following the first stage of resection for Patient 4. Both panels shown are axial. (*A*) Tw-weighted (FLAIR, fluid-attenuated inversion recovery); (*B*) T1 + Gd; (*C*) sagittal T1 + Gd. Although the majority of the tumor has been resected (blue arrows), a significant component remains (orange arrow), arising from the clivus.](MCS003418Lia_F4){#MCS003418LIAF4}

Exome sequencing revealed a subclonal missense *IGF1R* V721G mutation that was identified in 4% of reads. Expression of the mutation-containing transcript was also observed, with 11% of RNA reads supporting this event. A case study reported that an adult spinal chordoma patient who was treated with an investigational IGF1R/IR inhibitor linsitinib, in addition to the EGFR inhibitor erlotinib, remained stable on treatment for 5 yr ([@MCS003418LIAC2]). In a separate evaluation of dose escalation of linsitinib with erlotinib in solid tumors, a spinal chordoma patient also demonstrated a partial response to this combination ([@MCS003418LIAC37]). In Patient 4\'s tumor, both *EGF* and *EGFR* were expressed (FPKM = 50.9 and 70.0, respectively). Anti-IGF1R strategies continue to be explored in clinical trials.

A missense mutation in *PBRM1* (F408S) was also expressed in the tumor (DNA allele frequency = 0.24, RAF = 0.40). *PBRM1* encodes a component of complexes required for transcriptional activation via nuclear hormone receptors. Mutations in this gene are associated with renal cell carcinoma ([@MCS003418LIAC63]; [@MCS003418LIAC15]; [@MCS003418LIAC44]). In a targeted sequencing study, both deletion and missense mutation (S1315F) of *PBRM1* have been reported in chordomas ([@MCS003418LIAC62]).

Pathway Analysis {#s2c}
----------------

Pathway analysis on differentially expressed genes (corrected *P* \< 0.05) was additionally performed for each patient\'s tumor ([Supplemental Table S1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a003418/-/DC1); Patient 1 = 482 genes, Patient 2 = 615 genes, Patient 3 = 561 genes, Patient 4 = 482 genes). Although analysis did not yield significant (*P* \< 0.05) pathways that are specific to drug--gene matches for each patient, potentially interesting alterations were observed. In Patients 1 and 2, a potential immune component was revealed with the identification of T- and B-cell receptor pathways, and from a cohort-level analysis of all tumors, we observed additional commonly impacted processes across all tumors. These processes include ILK (integrin-linked kinase), integrin, and GTPase signaling, which are associated with the PI3K/Akt/mTor pathways; phospholipase C and calcium signaling pathways, which are associated with Fgf signaling; regulation of gene expression through the nuclear receptors FXR (farnesoid X receptor), TR (thyroid hormone receptor), LXR (liver X receptor), and RXR (retinoid X receptor); and what appear to be tumor microenvironment processes as defined by epithelial adherens junction signaling and tight junction signaling. Although ILK signaling has not been specifically reported in chordomas, obstructing β1 integrin function was suggested to be therapeutically relevant following radiation in chordomas ([@MCS003418LIAC24]). Separately, the importance of the microenvironment of chordomas has been previously demonstrated through in vitro analyses, whereby hypoxia combined with exposure to CCN2, a connective tissue growth factor, up-regulated notochord progenitor markers ([@MCS003418LIAC41]). Although limited conclusions may be drawn from expression data alone from this small cohort, these findings shed additional light into the intricacies of chordomas.

DISCUSSION {#s3}
==========

Our work demonstrates that integrated and comprehensive DNA and RNA profiling is practical on archival chordoma samples and that such an approach aids in the identification of potential candidate therapeutic targets. Previous genetic studies of chordoma have reported somatic abnormalities in genes such as *CDKN2A*, *PTEN*, *PIK3CA*, and *TP53* ([@MCS003418LIAC23]; [@MCS003418LIAC10]; [@MCS003418LIAC20]; [@MCS003418LIAC62]). Similar to previous studies, we did not observe highly recurrent somatic alterations; however, we identified alterations in genes that have been previously associated with chordoma, including *PBRM1* ([@MCS003418LIAC62]) and *IGF1R* ([@MCS003418LIAC54]; [@MCS003418LIAC47]). Incorporation of RNA-seq data was also beneficial, as it clarified which DNA alterations are expressed, and thus may serve as therapeutic targets. Based on comprehensive analyses, potential therapeutic strategies were identified across all patients. In the third patient, we identified germline base substitutions in *CHEK2* and *ATM*, which are likely key driving events in this tumor. With the availability of RNA-seq data, we additionally performed pathway analyses and identified processes that may be associated with potentially targetable pathways, although further studies are needed to determine if and how such processes may impact the efficacy of different treatments.

Overall, the data from this study, along with the results of previously published chordoma studies, provide evidence of aberrations converging on overlapping pathways. Although chordoma appears to be a genetically heterogeneous tumor, activation of common pathways may represent key exclusive events in this disease. These include the Ras-Raf-Mek and mTor pathways that lie downstream from IGF1R, EGFR, and FGFR signaling (Patients 1, 2, and 4), as well as cell cycle progression pathways that lie downstream from TP53, which is activated by CHEK2 and ATM (Patient 3) and CDK4/6 (Patient 2). Inhibition of IGF1R, EGFR, FGFR, and CDK4/6 thus represents possible treatment themes for chordoma ([@MCS003418LIAC43]; [@MCS003418LIAC54]). Targeting of the mTor pathway has also been suggested as a potential therapeutic strategy for chordoma ([@MCS003418LIAC43]).

Although we did not detect *EGFR* amplification or overexpression in the tumors analyzed here, targeting EGFR using erlotinib has shown promising results in two chordoma patients ([@MCS003418LIAC51]; [@MCS003418LIAC27]), one of whom was refractory to imatinib. Imatinib inhibited tumor growth in a patient-derived chordoma xenograft ([@MCS003418LIAC52]), and in a separate Phase 2 study, imatinib inhibited tumor growth in previously progressive patients expressing PDGFB/PDGFRB ([@MCS003418LIAC55]; [@MCS003418LIAC26]); both of these markers were expressed in the patients analyzed here but did not demonstrate significant overexpression in the tumors compared to a universal RNA control. Notably, the EGFR inhibitor afatinib is currently being evaluated in a Phase 2 trial for chordoma patients with EGFR-expressing tumors (NCT03083678) and also appears to be active in the central nervous system in non-small-cell lung carcinoma patients ([@MCS003418LIAC30]). Last, for Patient 3, who appears to have germline disease, potential strategies for consideration include PARP inhibition and ATM inhibition combined with radiation, though ATM inhibitors are not yet FDA-approved.

Although our study sheds further light onto chordoma and potential treatment options, a number of limitations are apparent. The first is our small sample size, which is directly related to the rare nature of the malignancy and the availability of archival specimens. Second, given the diversity of mutations previously reported in chordoma and those reported here, additional analyses are needed to understand the role of identified mutations in altering functional pathways and how such perturbed pathways enable tumor development and progression in chordoma. Additional studies are also needed to evaluate efficacy and prioritization of candidate single-agent strategies and to explore potential use of combination therapies in this disease.

Even so, despite the rarity of chordoma, previous studies and our analysis here shed valuable light on our understanding of the disease. As the majority of previous chordoma sequencing studies have used targeted sequencing approaches that lack integrated transcriptomic analyses, we present analysis from a unique data set that integrates whole-genome, whole-exome, and whole-transcriptome data across patients. This analysis is thus the first to integrate both DNA and RNA sequencing data in sacral and clivus chordomas and also provides evidence of convergence of alterations in specific pathways. Notably, current clinical trials that are open to chordoma patients are focused on targeting brachyury (NCT02383498), PD-1/PD-L1 (NCT03173950, NCT02989636), SMARCB1/INI-1 (NCT02601950), and CDK4/6 (NCT03110744). Our analyses lend further credence to CDK4/6 inhibition and suggest that targeting IGF1R/EGFR/FGFR signaling may be a new candidate therapeutic strategy. Such convergence and continued molecular characterization of chordomas has the potential to improve our ability to find effective treatment strategies for patients.

METHODS {#s4}
=======

Clinical Details {#s4a}
----------------

De-identified clinical histories, pathology reports, and MRI results were reviewed for each patient. For patients who received care at another institution, some of the records were incomplete.

Sample Collection and Extraction {#s4b}
--------------------------------

Chordomas, embedded in optimal cutting temperature compound, and matched whole blood were retrieved from the Biobank Core Facility of the Barrow Neurological Institute at St. Joseph\'s Hospital and Medical Center. The tissue was homogenized using the Bullet Blender (Next Advance, Inc.) and stainless-steel beads. The lysate was further homogenized using the QIAshredder (QIAGEN) and digested with proteinase K. For nucleic acid purification, we used the AllPrep DNA/RNA Mini Kit (QIAGEN), which allows for the simultaneous purification of genomic DNA and total RNA from the same biological sample. Germline DNA was extracted from whole blood using the Gentra Puregene Blood Kit, 3rd edition (QIAGEN), following the manufacturer\'s instructions, including RNase A treatment.

Next-Generation Sequencing {#s4c}
--------------------------

Paired tumor/normal exomes were constructed using SureSelectXT Human All Exon V5+UTR baits (Agilent). The KAPA Library Preparation Kit (Kapa Biosystems) was used for Patient 1 and the KAPA HyperPrep Kit (Kapa Biosystems) was used for Patients 2--4. Paired tumor/normal LIWGs were constructed using the KAPA HyperPrep Kit, as previously described ([@MCS003418LIAC33], [@MCS003418LIAC34]). Tumor RNA was used to generate RNA libraries using the TruSeq RNA Access Library Prep Kit (Illumina). The libraries were paired-end sequenced using the TruSeq PE Cluster Kit v3 and the TruSeq SBS Kit v3 (Illumina) on the HiSeq 2500 (Illumina) for 2 × 109 bp reads with a 7-base index read.

Data Analysis {#s4d}
-------------

Binary base call files were converted to FASTQ files using bcl2fastq Conversion Software (Illumina) v1.8-2.17.1.14. The FASTQ files were aligned to the human reference genome (GRCh37) using the Burrows--Wheeler Aligner ([@MCS003418LIAC32]). Somatic analyses were performed as previously described using an annotation pipeline built on GENCODE 3 (Ensembl; GRCh37.1) ([@MCS003418LIAC34]; [@MCS003418LIAC65]). To determine whether tumor single-nucleotide variants (SNVs) were present, we used the consensus of at least two of the three following tools: Seurat, a Bayesian framework ([@MCS003418LIAC11]) (threshold quality score of \>30), MuTect, a Bayesian classifier ([@MCS003418LIAC13]), and Strelka, a somatic small-variant tool ([@MCS003418LIAC46]). Tumor cellularities, or purities, for each sample were estimated in silico using Sequenza ([@MCS003418LIAC19]). MutationTaster ([@MCS003418LIAC49]), PolyPhen-2 ([@MCS003418LIAC1]), and FATHMM ([@MCS003418LIAC50]) were used to predict the impact of identified base substitutions.

DNA copy number and breakpoint detection were assessed using LIWG data ([@MCS003418LIAC33]). For copy-number variation (CNV) detection, (1) read depths were determined every 100 bases across sequenced regions; (2) normalized log~2~ fold changes between the tumor and germline were calculated; and (3) a smoothing window was applied. The circular binary segmentation algorithm was used to partition chromosomes into sections of equal copy number to correct for noise in order to calculate log~2~ copy fold changes ([@MCS003418LIAC40]).

RNA reads were aligned to GRCh37 using STAR ([@MCS003418LIAC17]). Differential expression analysis was performed for each tumor sample against Universal Human Reference RNA (Agilent) using Cufflinks/Cuffdiff ([@MCS003418LIAC59]), which performs transcript assembly to identify differentially expressed genes, and DESeq2 ([@MCS003418LIAC4]; [@MCS003418LIAC36]), which uses the negative binomial distribution. False discovery rate adjustment of *P*-values for expression changes were performed to calculate a *Q*-value, or a corrected *P*-value, using the Benjamini--Hochberg correction for multiple testing. Expression levels are expressed as fragments per kilobase of transcript per million mapped reads (FPKMs). We defined a threshold FPKM value of \>1 to indicate expression of a gene.

Pathway analysis was performed using differentially expressed genes (corrected *P* \< 0.05) identified using both Cuffdiff and DESeq2. Analysis was performed using the Ingenuity Pathway Analysis (IPA) tool (version 01-12; QIAGEN) to identify potentially perturbed pathways in each tumor. Significant pathways were identified with *P* \< 0.05. In a separate analysis for Patient 1, KEGG networks N00019 (FGF-FGFR-RAS-ERK signaling pathway) and N00037 (FGF-FGFR-PI3K signaling pathway) were used to identify factors downstream from FGFR; interrogated genes include *GRB2*, *SOS1*, *SOS2*, *HRAS*, *KRAS*, *NRAS*, *ARAF*, *BRAF*, *RAF1*, *MAP2K1*, *MAP2K2*, *MAPK1*, *MAPK3*, *PIK3CA*, *PIK3CB*, *PIK3CD*, *AKT1*, *AKT2*, *AKT3*, *MTOR*, *RPS6KB1*, and *RPS6KB2*.

Drug--Gene Matching {#s4e}
-------------------

All somatic aberrations identified through LIWG, exome, and RNA sequencing data, including SNVs, small indels (insertion/deletions), CNVs, translocations, gene fusions, and RNA expression changes, were evaluated for each case. Potential therapeutic implications for RNA expression events are limited to genes that are differentially expressed compared to the Universal Human Reference RNA (corrected *P* \< 0.05). For any abnormalities identified, we looked for potential therapies using a proprietary drug--gene database annotated with a pharmacopeia of FDA-approved agents. Genes and alterations associated with FDA-approved agents are reported here.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

The sequencing data generated from this study are available in the NCBI (National Center for Biotechnology Information) dbGaP (Database of Genotypes and Phenotypes) repository (<https://www.ncbi.nlm.nih.gov/gap>) under controlled access (accession number phs001643).
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